Inactivation Or Attenuation; Producing Viral Subunits Patents (Class 435/236)
-
Patent number: 8282937Abstract: The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously published sequences for cold-adapted A/Ann Arbor/6/60 genes. The cold-adapted live influenza virus of the present invention can be reasserted with a variety of epidemic wild type influenza viruses and used to produce vaccines to prophylactically and therapeutically treat influenza.Type: GrantFiled: March 23, 2007Date of Patent: October 9, 2012Assignee: The Regents of the University of MichiganInventors: Hunein Maassab, Martha Louise Herlocher
-
Publication number: 20120251502Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.Type: ApplicationFiled: October 26, 2009Publication date: October 4, 2012Applicant: The Government of the US as Represented by the Secretary of the Dept. of healthInventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
-
Publication number: 20120251568Abstract: Described herein are modified influenza virus NS gene segments and nucleic acid sequences encoding such modified influenza virus NS gene segments. In certain embodiments, a modified influenza virus NS gene segment described herein comprises an influenza virus NS 1 open reading frame (ORF) lacking a stop codon, a heterologous nucleotide sequence, a 2A autoproteolytic cleavage site or another cleavage site, an NEP ORF, wherein the gene segment has one or more mutations in either the splice acceptor site, splice donor site, or both the splice acceptor and splice donor sites that prevents splicing of mRNA. Also described herein are recombinant influenza viruses comprising a modified influenza virus NS gene segment and the use of such viruses. The recombinant influenza viruses may be use in the prevention and/or treatment of influenza virus disease or as a delivery vector.Type: ApplicationFiled: July 27, 2010Publication date: October 4, 2012Inventors: Adolfo Garcia-Sastre, Peter Palese, Balaji Manicassamy
-
Publication number: 20120244180Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-15Ra or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.Type: ApplicationFiled: September 14, 2010Publication date: September 27, 2012Inventors: David B. Weiner, Kimberly A. Kraynyak, Michele Kutzler
-
Publication number: 20120244183Abstract: Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and/or treatment of influenza virus disease.Type: ApplicationFiled: July 29, 2010Publication date: September 27, 2012Inventors: Adolfo Garcia-Sastre, Peter Palese, Qinshan Gao
-
Publication number: 20120237543Abstract: The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Phillip Wayne HAYES, Kristina J. HENNESSY, Laurent VIEL, Andres DIAZ-MENDEZ
-
Publication number: 20120237545Abstract: A combination of ultrafiltration and HPLC is used to analyze influenza virus. This combination is able to quantify hemagglutinin (HA) and correlates well with single radial immunodiffusion (SRID) results, but can be performed without the delay of waiting for immunochemical SRID reagents.Type: ApplicationFiled: May 28, 2010Publication date: September 20, 2012Applicant: NORVARTIS AGInventors: Philip Dormitzer, Yingxia Wen, Paola Rinella, Gene Palmer
-
Patent number: 8268602Abstract: The invention provides compositions of inactivated viruses, bacteria, fungi, parasites and tumor cells that can be used as vaccines. Methods for making such inactivated viruses, bacteria, fungi, parasites and tumor cells are also provided.Type: GrantFiled: September 21, 2006Date of Patent: September 18, 2012Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Yossef Raviv, Mathias Viard, Robert Blumenthal
-
Publication number: 20120201852Abstract: The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.Type: ApplicationFiled: October 3, 2011Publication date: August 9, 2012Applicant: Sanofi Pasteur Biologics Co.Inventors: Farshad Guirakhoo, J. Jian Liu, John A. Catalan, Thomas P. Monath, Konstantin V. Pugachev
-
Publication number: 20120201850Abstract: The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.Type: ApplicationFiled: February 1, 2012Publication date: August 9, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Knut Elbers, Christiane Meyer, Martina von Freyburg, Gregor Meyers
-
Publication number: 20120189659Abstract: This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein ERNS is inactivated, as well as methods of preparing, using and detecting these pestiviruses.Type: ApplicationFiled: May 5, 2011Publication date: July 26, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Gregor MEYERS
-
Publication number: 20120171660Abstract: The present invention relates to methods for screening or purifying enteroviruses, a method for mass-producing enteroviruses, and a method for manufacturing an enterovirus vaccine. The method for screening enteroviruses in a sample comprises the following steps: (A) providing a sample and a carrier, wherein monosaccharides such as glucose or galactose are bound to the surface of the carrier, and the monosaccharides have binding affinity to enterovirus; (B) contacting the sample with the carrier; (C) removing components of the sample that do not bind to the carrier; (D) providing a detection unit and contacting the detection unit with the carrier, wherein the detection unit binds to the sample bound on the carrier; and (E) measuring a signal of the detection unit, wherein when the signal of the detection unit is detected, it represents that the enterovirus exists in the sample.Type: ApplicationFiled: July 14, 2011Publication date: July 5, 2012Applicant: National Cheng Kung UniversityInventors: Huan-Yao LEI, Chia-Ming Liu
-
Publication number: 20120172418Abstract: The invention provides a viral self-inactivating (SIN) vector on the basis of the avian sarcoma leukosis virus (ASLV) as well as a split-packaging system comprising in addition to the SIN vector a first helper plasmid serving for the expression of the viral fusion protein gag-pol and a second helper plasmid serving for the expression of the retroviral envelope protein (env). The first and second helper plasmid, for example contained in a packaging cell line or transiently transfected, serve for the generation of non-replicating (RCR-incompetent) viral particles containing RNA having a SIN LTR according to the invention at the 3? terminus, wherein the RNA can have a therapeutically effective section which e.g. is denoted a transgene. This 3? SIN LTR contains an extensive deletion of the U3 region which in the course of the reverse transcription is copied into the 5? LTR. In addition, in the SIN vector all coding regions of ASLV as well as the retroviral splice donor site are removed.Type: ApplicationFiled: May 17, 2010Publication date: July 5, 2012Applicant: Medizinische Hochscule HannoverInventors: Axel Schambach, Christopher Baum, Julia Suerth
-
Publication number: 20120171243Abstract: Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a recombinant non-toxic protein and a wild type non-toxic protein, and genes encoding toxic proteins, HA (hemagglutinin) and NA (neuraminidase), of an influenza virus, the recombinant non-toxic protein consisting of a substituted caspase recognition sequence without a change of a protein size within the wild type non-toxic protein of the influenza virus. The disclosed attenuated influenza virus shows a high attenuation without a reduction of productivity in a fertilized egg. Accordingly, the method can be used as an economically efficient live vaccine preparation method which has both safety and efficiency and can use a fertilized egg as a production system.Type: ApplicationFiled: August 22, 2011Publication date: July 5, 2012Applicant: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Baik Lin Seong, Yo Han Jang, Kwang Hee Lee, Young Ho Byun
-
Publication number: 20120164170Abstract: The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.Type: ApplicationFiled: December 20, 2011Publication date: June 28, 2012Inventors: Tsun-Yung KUO, Hsu Chung Gabriel Chen, Chung-Chin Wu, Han-Ting Chen
-
Patent number: 8178087Abstract: A method for producing bacteriophage stock compositions including (a) incubating a culture medium including at least one bacterial strain, at least one bacteriophage strain that can infect the bacterial strain, and at least one antibiotic, wherein the concentration of the antibiotic in the medium is in a range which causes about 0.1% to about 99.9% inhibition of the growth of the bacterial strain in the absence of the bacteriophage strain; (b) continuing incubation of the culture medium until bacterial lysis occurs, thereby obtaining a bacteriophage lysate; and preparing a crude bacteriophage extract from the culture medium.Type: GrantFiled: April 3, 2007Date of Patent: May 15, 2012Assignees: Centre National de la Recherche Scientifique —CNRS, Universite Paul Sabatier de Toulouse 3Inventors: Henry M. Krisch, Marie-Françoise Prere, Françoise Tetart
-
Publication number: 20120114694Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.Type: ApplicationFiled: September 22, 2011Publication date: May 10, 2012Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
-
Publication number: 20120115206Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: ApplicationFiled: January 20, 2012Publication date: May 10, 2012Applicant: Medlmmune WayInventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
-
Publication number: 20120107356Abstract: Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children.Type: ApplicationFiled: January 25, 2010Publication date: May 3, 2012Applicant: BHARAT BIOTECH INTERNATIONAL LIMITEDInventors: Krishna Mohan Vadrevu, Selvi Veerabadran, Sai Devarajulu Prasad
-
Publication number: 20120100181Abstract: The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, ˜35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, CVEE30-68, includes two domains with distinguished functions. The integrity of both domains determines not only the intracellular distribution of CVEE, but is also essential for direct capsid function in the inhibition of transcription. The replacement of the N-terminal fragment of CVEE by its SINV-specific counterpart in VEEV TC-83 genome does not affect virus replication in vitro, but makes it less cytopathic and more attenuated in vivo.Type: ApplicationFiled: October 28, 2011Publication date: April 26, 2012Applicant: The Board of Regents of the University of Texas SystemInventors: Ilya V. Frolov, Elena Frolova, Scott C. Weaver
-
Publication number: 20120100576Abstract: The present invention pertains to a system for culturing cells comprising a culturing bag and a continuous flow centrifuge wherein the cells are continuously separated from the supernatant and are recycled into the culturing bag. Further provided are methods for culturing cells and for producing a biological substance using the device for culturing cells, and the use of a bag for culturing cells in said device or said methods. In particular, a perfusion system for culturing cells is provided wherein the wave technology for culturing cells is combined with continuous flow centrifugation for separating the medium from the cells.Type: ApplicationFiled: July 8, 2010Publication date: April 26, 2012Applicant: GLYCOTOPE GMBHInventors: Steffen Goletz, Rainer Stahn, Annett Hillemann
-
Patent number: 8163530Abstract: The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.Type: GrantFiled: July 23, 2009Date of Patent: April 24, 2012Assignee: MedImmune, LLCInventors: Xing Cheng, Hyun Jung Park, Hong Jin
-
Patent number: 8142714Abstract: The invention relates to the use of a cleaning agent that contains surfactants and has a pH value of at least 11 when diluted in an aqueous solution and ready for use. Said cleaning agent is used to destabilize prions during mechanical and manual cleaning and/or disinfection of medical and/or surgical instruments and appliances. It has been recognized that this combination enables a reliable destabilization of prions during the mechanical reconditioning of surgical instruments.Type: GrantFiled: January 28, 2003Date of Patent: March 27, 2012Assignee: Chemische Fabrik Dr. Weigert GmbH & Co. KGInventors: Petra Tiarks, Jurgen Staffeldt
-
Publication number: 20120058145Abstract: A method of purifying a virus, or a viral antigen thereof, from a culture of infected cells comprising at least the steps of: (a) collecting the virus-containing cell culture medium, and (b) purifying the virus, wherein at least one homogenization step is implemented during the purification to obtain a virus homogenate.Type: ApplicationFiled: May 6, 2010Publication date: March 8, 2012Inventors: Bruno Rene Andre, Benoit Paul Suzanne Champluvier
-
Patent number: 8128937Abstract: The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified virus and polynucleotides are also provided.Type: GrantFiled: March 30, 2009Date of Patent: March 6, 2012Assignee: Pfizer Inc.Inventors: Dongwan Yoo, Changhee Lee, Jay Gregory Calvert, Siao-Kun Welch
-
Publication number: 20120045468Abstract: Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods.Type: ApplicationFiled: August 17, 2010Publication date: February 23, 2012Applicant: National Health Research InstitutesInventors: Pele Choi-Sing Chong, Chia-Chyi Liu, Meng-Shin Kuo, Ray Jui-Yuan Chang
-
Patent number: 8119388Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: GrantFiled: January 13, 2010Date of Patent: February 21, 2012Assignee: Medimmune, LLCInventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
-
Publication number: 20120039921Abstract: The present invention provides materials and methods for researching poultry viruses, particularly for researching infectious bronchitis viruses in poultry. Also provided are materials and methods useful for reducing the economic impact that infectious bronchitis disease has on poultry production. In one aspect of the invention, there are provided nucleic acids, amino acids and related materials and compositions useful for combating infectious bronchitis virus in poultry.Type: ApplicationFiled: November 22, 2010Publication date: February 16, 2012Inventors: HOLLY S. SELLERS, MARK JACKWOOD
-
Patent number: 8114852Abstract: E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation.Type: GrantFiled: January 15, 2008Date of Patent: February 14, 2012Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Manuel Borca, Guillermo Risatti
-
Publication number: 20120034265Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: September 28, 2011Publication date: February 9, 2012Applicant: MEDIMMUNE, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20120034267Abstract: The invention provides an inactivated varicella zoster virus (VZV), and compositions and vaccines comprising said inactivated VZV, wherein the infectivity of the VZV is undetectable and wherein the inactivated VZV induces an immune response against VZV when administered to a patient. In embodiments of the compositions described herein, the VZV is inactivated with gamma radiation. The invention also provides a method of preparing an inactivated VZV vaccine, the method comprising gamma irradiating a sample comprising a VZV using from about 5 kGy to about 50 kGy of gamma radiation. Also provided by the invention herein is a method of treatment of or immunization against HZ or other disease associated with the reactivation of VZV, the method comprising administering to a subject a vaccine or pharmaceutical composition comprising a therapeutically effective amount of an inactivated VZV and a pharmaceutically acceptable carrier, wherein the VZV is inactivated by gamma irradiation.Type: ApplicationFiled: August 4, 2011Publication date: February 9, 2012Inventors: David L. Krah, Jill DeHaven, Jennifer A. Kriss, Colleen M. Barr, Mary Yagodich
-
Publication number: 20120034264Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: June 16, 2011Publication date: February 9, 2012Applicant: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Publication number: 20120027777Abstract: The present invention relates to a Ljungan virus with improved replication characteristic and the use of this Ljungan virus, amongst other thing, in the production of a vaccine.Type: ApplicationFiled: January 22, 2010Publication date: February 2, 2012Applicant: APODEMUS ABInventors: Michael Lindberg, Conny Tolf
-
Publication number: 20120027846Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.Type: ApplicationFiled: July 28, 2011Publication date: February 2, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Brian AGNEW, David GRAHAM, Upinder SINGH, Scott GRECIAN
-
Patent number: 8105609Abstract: The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention.Type: GrantFiled: May 16, 2008Date of Patent: January 31, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventor: Gwong-Jen J. Chang
-
Publication number: 20120020997Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.Type: ApplicationFiled: August 19, 2011Publication date: January 26, 2012Inventors: Erich Hoffman, Hong Jin, Bin Lu, Greg Duke, George Kemble
-
Publication number: 20120014992Abstract: E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation.Type: ApplicationFiled: September 21, 2011Publication date: January 19, 2012Inventors: Manuel Borca, Guillermo Risatti
-
Publication number: 20120009654Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.Type: ApplicationFiled: September 16, 2011Publication date: January 12, 2012Inventors: Anton MAYR, Barbara MAYR
-
Patent number: 8088391Abstract: The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection.Type: GrantFiled: March 23, 2009Date of Patent: January 3, 2012Assignee: Sanofi Pasteur Biologics Co.Inventors: Juan Arroyo, Charles Miller, John Avram Catalan, Thomas P. Monath
-
Publication number: 20110311579Abstract: This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs for production and delivery.Type: ApplicationFiled: July 22, 2011Publication date: December 22, 2011Inventors: Peter W. Mason, Tomohiro Ishikawa
-
Publication number: 20110311586Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: ApplicationFiled: April 19, 2011Publication date: December 22, 2011Applicants: University of Florida Research Foundation, Inc., Intervet International B.V., The Govt. of the U.S.A. as represented by The Secretary of the Dept. of Health & Human Services, Cornell Research Foundation, Inc.Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, William L. Castleman, Nancy J. Cox
-
Publication number: 20110305726Abstract: The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live, attenuated IB viruses of the invention may be produced by serial passaging of an IB-QX-like virus. The IB viruses of the invention are useful for, inter alia, vaccines against IB-QX and IB-QX-like viruses. Heretofore, known vaccine strains of IB viruses have proven insufficient to protect against infectious bronchitis caused by IB-QX and IB-QX-like viruses.Type: ApplicationFiled: August 7, 2009Publication date: December 15, 2011Applicant: Wyeth LLCInventors: Harmen Jacob Geerligs, Cindy Aleida Maria Meinders, Geert Jan Boelm, Bastiana Geertruida Elisabeth Stuurman
-
Patent number: 8075903Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: March 4, 2009Date of Patent: December 13, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
-
Publication number: 20110293660Abstract: The present invention relates to a method for purifying a virus, or a viral antigen thereof, comprising at least the following steps: a) obtaining a fluid comprising the virus, or a viral antigen thereof, and b) purifying the fluid by at least one density gradient ultracentrifugation step, wherein the ratio of the amount of virus, or viral antigen thereof, present in the fluid over the density gradient volume is less than 1, less than 0.8, less than 0.6 and less than 0.4.Type: ApplicationFiled: February 4, 2010Publication date: December 1, 2011Inventors: Bruno Rene Andre, Benoit Paul Suzanne Champluvier
-
Publication number: 20110287050Abstract: The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and to a vaccine for preventive and/or therapeutic treatment of a disease caused by koi herpesvirus (KHV) or CyHV-3. The 5 recombinant herpesvirus is used to confer immunity on fish, preferably on carps, more preferably on Cyprinus carpio, against a disease caused by koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3).Type: ApplicationFiled: August 26, 2008Publication date: November 24, 2011Applicant: Universite de Liege, Faculty of Veterinary Medicine immunology-VaccinologyInventors: Berenice Costes, Alain Francis Claude Vanderplasschen, Francois Lieffrig
-
Publication number: 20110280905Abstract: The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD).Type: ApplicationFiled: March 16, 2011Publication date: November 17, 2011Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.Inventors: XIANG-JIN MENG, NATHAN M. BEACH, SHEELA RAMAMOORTHY
-
Publication number: 20110274661Abstract: The disclosure provides materials and methods for the treatment of cells exhibiting a cell proliferative disorder with a herpes simplex virus having a deficiency in the expression of active ICP34.5 and comprising an expression control element effective in modulating at least one component of the MEK pathway to ensure that infected cells are MEK+. Cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, are amenable to treatment using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.Type: ApplicationFiled: August 7, 2009Publication date: November 10, 2011Applicant: The University of ChicagoInventors: Alice P. Poon, Ralph R. Weichselbaum, Bernard Roizman
-
Publication number: 20110262474Abstract: The invention provides polynucleotides and polypeptides encoded therefrom that are capable of inducing immune responses to a human immunodeficiency virus. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: ApplicationFiled: July 23, 2008Publication date: October 27, 2011Inventors: Xiaohan Du, Li Xu, Robert Whalen, Kristin M. Ostrow
-
Publication number: 20110256174Abstract: An attenuated rabies virus for use as a vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the vaccine.Type: ApplicationFiled: April 26, 2011Publication date: October 20, 2011Inventor: Zhen F. FU
-
Patent number: 8039003Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.Type: GrantFiled: March 2, 2009Date of Patent: October 18, 2011Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney